Dr. Symmans is Professor and Director of Research Operations in the Department of Pathology at MD Anderson Cancer Center in Houston TX, where he practices Breast Surgical Pathology and Cytopathology and directs the Breast Cancer Pharmacogenomics Laboratory. He received his medical degree from the University of Auckland, New Zealand, completed his residency at Columbia University, New York, and fellowship at MD Anderson Cancer Center, Houston. Dr. Symmans joined the faculty of New York University Medical Center in 1993 and moved to MD Anderson Cancer Center in 2000. Dr. Symmans serves on the Steering Committee for the Translational Breast Cancer Research Consortium, is the Principal Investigator and Director of the Translational Research Program for the National Alliance for Clinical Trials cooperative group, and is a voting member of both, the Breast Cancer Steering Committee and the Correlative Sciences Review Committee for the National Clinical Trials Evaluation Program, National Cancer Institute. He is a funded researcher of the Breast Cancer Research Foundation (BCRF).
Dr. Symmans’ research is focused on breast cancer: neoadjuvant (pre-operative) treatment trials for evaluation of chemo-sensitivity and development of diagnostic tests to select the most effective treatments. Dr. Symmans is the lead inventor of Delphi’s product line and plays a pivotal role by driving the research underlying the Delphi products.
Dr. Symmans will hold shares in Delphi Diagnostics Inc., but his employment with MD Anderson Cancer Center precludes him from being an employee, paid consultant or officer of Delphi Diagnostics.